SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-049089
Filing Date
2024-04-26
Accepted
2024-04-26 16:05:22
Documents
7
Period of Report
2024-06-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A achv_2024_proxy-def14a.htm DEF 14A 942820
2 GRAPHIC img185693128_0.jpg GRAPHIC 22710
3 GRAPHIC img185693128_1.jpg GRAPHIC 155426
4 GRAPHIC img185693128_2.jpg GRAPHIC 153645
5 GRAPHIC img185693128_3.jpg GRAPHIC 22710
6 GRAPHIC img185693128_4.jpg GRAPHIC 553308
7 GRAPHIC img185693128_5.jpg GRAPHIC 431784
  Complete submission text file 0000950170-24-049089.txt   2788496
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 033-80623 | Film No.: 24883535
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)